Déjà vu: Stimulating open drug discovery for SARS-CoV-2.
Drug Discov Today
; 25(5): 928-941, 2020 05.
Article
in English
| MEDLINE | ID: covidwho-72302
ABSTRACT
In the past decade we have seen two major Ebola virus outbreaks in Africa, the Zika virus in Brazil and the Americas and the current pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is a strong sense of déjà vu because there are still no effective treatments. In the COVID-19 pandemic, despite being a new virus, there are already drugs suggested as active in in vitro assays that are being repurposed in clinical trials. Promising SARS-CoV-2 viral targets and computational approaches are described and discussed. Here, we propose, based on open antiviral drug discovery approaches for previous outbreaks, that there could still be gaps in our approach to drug discovery.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Pneumonia, Viral
/
Coronavirus Infections
/
Drug Discovery
/
Betacoronavirus
Type of study:
Prognostic study
Limits:
Animals
/
Humans
Language:
English
Journal:
Drug Discov Today
Journal subject:
Pharmacology
/
Drug Therapy
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS